. 2012 Oct; 23 Suppl 6:vi46-51.
doi: 10.1093/annonc/mds195.

Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents

F André 1 C C Zielinski  
  • PMID: 23012302
  •     107 citations


Triple-negative breast cancer (TNBC) is an aggressive histological subtype with limited treatment options and very poor prognosis following progression after standard chemotherapeutic regimens. Resistance to current standard therapies such as anthracyclines or taxanes limits the available options for previously treated patients with metastatic TNBC to a small number of non-cross-resistant regimens, and there is currently no preferred standard chemotherapy. Duration of response is usually short, with rapid relapse very common and median survival of just 13 months. The newly approved agent eribulin has shown a survival benefit in patients who had previously been treated with anthracycline- or taxane-containing regimens, including in patients with TNBC. Platinum-based regimens are an emerging option for patients with BRCA1 mutation, and newer targeted agents such as anti-angiogenic treatment with bevacizumab or anti-epidermal growth factor receptor treatment with cetuximab, have shown some benefit in combination therapy. However, there remains an urgent unmet need for improved targeted agents for this patient population. Improved treatment may be facilitated by biomarker-led understanding of subgroup molecular targets, which may predict benefit from currently approved agents, as well as newer targeted drugs.

Evolving approaches to metastatic breast cancer patients pre-treated with anthracycline and taxane.
Shigehira Saji.
BioDrugs, 2013 May 10; 27(5). PMID: 23658121    Free PMC article.
Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells.
Rajeshwari Mehta, Harshadadevi Katta, +5 authors, Rajendra G Mehta.
PLoS One, 2013 Jun 14; 8(6). PMID: 23762292    Free PMC article.
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer.
Rebecca A Dent, Geoffrey J Lindeman, +7 authors, James Carmichael.
Breast Cancer Res, 2013 Sep 26; 15(5). PMID: 24063698    Free PMC article.
Highly Cited.
Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine.
Sarah Derks, Arjen H G Cleven, +7 authors, Manon van Engeland.
Cancer Metastasis Rev, 2014 Jan 01; 33(1). PMID: 24375389    Free PMC article.
Imaging the urokinase plasminongen activator receptor in preclinical breast cancer models of acquired drug resistance.
Aaron M LeBeau, Natalia Sevillano, +5 authors, Henry F VanBrocklin.
Theranostics, 2014 Feb 08; 4(3). PMID: 24505235    Free PMC article.
Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer.
Jessica J Tao, Pau Castel, +23 authors, Maurizio Scaltriti.
Sci Signal, 2014 Mar 29; 7(318). PMID: 24667376    Free PMC article.
Noninvasive theranostic imaging of HSV1-sr39TK-NTR/GCV-CB1954 dual-prodrug therapy in metastatic lung lesions of MDA-MB-231 triple negative breast cancer in mice.
Thillai V Sekar, Kira Foygel, Ohad Ilovich, Ramasamy Paulmurugan.
Theranostics, 2014 Mar 29; 4(5). PMID: 24669276    Free PMC article.
MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer.
Mao Ouyang, Yongxin Li, +8 authors, Wenjian Wang.
PLoS One, 2014 May 03; 9(5). PMID: 24788655    Free PMC article.
Highly Cited.
Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer.
Christine Mehner, Alexandra Hockla, +3 authors, Evette S Radisky.
Oncotarget, 2014 May 09; 5(9). PMID: 24811362    Free PMC article.
Highly Cited.
Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer.
L Alexis Hoeferlin, Charles E Chalfant, Margaret A Park.
J Surg Sci, 2014 May 13; 1(1). PMID: 24818173    Free PMC article.
MicroRNA-200b targets protein kinase Cα and suppresses triple-negative breast cancer metastasis.
Brock Humphries, Zhishan Wang, +5 authors, Chengfeng Yang.
Carcinogenesis, 2014 Jun 14; 35(10). PMID: 24925028    Free PMC article.
Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells.
Guelaguetza Vazquez-Ortiz, Cristine Chisholm, +7 authors, Chuxia Deng.
Breast Cancer Res, 2014 Jun 26; 16(3). PMID: 24962108    Free PMC article.
Mesenchymal stem cell-induced doxorubicin resistance in triple negative breast cancer.
Dar-Ren Chen, Dah-Yuu Lu, Hui-Yi Lin, Wei-Lan Yeh.
Biomed Res Int, 2014 Aug 21; 2014. PMID: 25140317    Free PMC article.
Optimization of Aqueous Biphasic Tumor Spheroid Microtechnology for Anti-Cancer Drug Testing in 3D Culture.
Stephanie Lemmo, Ehsan Atefi, Gary D Luker, Hossein Tavana.
Cell Mol Bioeng, 2014 Sep 16; 7(3). PMID: 25221631    Free PMC article.
Capecitabine maintenance therapy for XT chemotherapy-sensitive patients with metastatic triple-negative breast cancer.
Xu Liang, Lijun Di, +4 authors, Huiping Li.
Chin J Cancer Res, 2014 Nov 18; 26(5). PMID: 25400420    Free PMC article.
Combined phosphoproteomics and bioinformatics strategy in deciphering drug resistant related pathways in triple negative breast cancer.
Xinyu Deng, Morris Kohanfars, +4 authors, Helena R Chang.
Int J Proteomics, 2014 Dec 06; 2014. PMID: 25478227    Free PMC article.
Evaluating the evidence for targeting FOXO3a in breast cancer: a systematic review.
Simon Taylor, Matthew Lam, +3 authors, Helen R Griffiths.
Cancer Cell Int, 2015 Feb 14; 15(1). PMID: 25678856    Free PMC article.
Simultaneous inhibition of deubiquitinating enzymes (DUBs) and autophagy synergistically kills breast cancer cells.
Rachel Isaksson Vogel, Kathleen Coughlin, +5 authors, Martina Bazzaro.
Oncotarget, 2015 Mar 19; 6(6). PMID: 25784654    Free PMC article.
Development of a Fluorescent Reporter System to Delineate Cancer Stem Cells in Triple-Negative Breast Cancer.
Praveena S Thiagarajan, Masahiro Hitomi, +14 authors, Ofer Reizes.
Stem Cells, 2015 Apr 02; 33(7). PMID: 25827713    Free PMC article.
Application of a drug-induced apoptosis assay to identify treatment strategies in recurrent or metastatic breast cancer.
Linda Bosserman, Karl Rogers, +8 authors, Cary A Presant.
PLoS One, 2015 May 30; 10(5). PMID: 26024531    Free PMC article.
Platinum-based therapy for triple-negative breast cancer treatment: A meta-analysis.
Muyou Tian, Yahua Zhong, +3 authors, Zhengkai Liao.
Mol Clin Oncol, 2015 Jul 03; 3(3). PMID: 26137293    Free PMC article.
The small GTPase ADP-Ribosylation Factor 1 mediates the sensitivity of triple negative breast cancer cells to EGFR tyrosine kinase inhibitors.
Eric Haines, Sabrina Schlienger, Audrey Claing.
Cancer Biol Ther, 2015 Jul 16; 16(10). PMID: 26176330    Free PMC article.
Enhanced cytotoxicity in triple-negative and estrogen receptor‑positive breast adenocarcinoma cells due to inhibition of the transient receptor potential melastatin-2 channel.
David W Koh, Daniel P Powell, +3 authors, Xiaoxing Feng.
Oncol Rep, 2015 Jul 17; 34(3). PMID: 26178079    Free PMC article.
Chemotherapy triggers HIF-1-dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype.
Haiquan Lu, Debangshu Samanta, +5 authors, Gregg L Semenza.
Proc Natl Acad Sci U S A, 2015 Aug 01; 112(33). PMID: 26229077    Free PMC article.
Highly Cited.
Implications of the Hybrid Epithelial/Mesenchymal Phenotype in Metastasis.
Mohit Kumar Jolly, Marcelo Boareto, +5 authors, Herbert Levine.
Front Oncol, 2015 Aug 11; 5. PMID: 26258068    Free PMC article.
Highly Cited. Review.
The role of taxanes in triple-negative breast cancer: literature review.
Giorgio Mustacchi, Michelino De Laurentiis.
Drug Des Devel Ther, 2015 Aug 15; 9. PMID: 26273192    Free PMC article.
Triple negative breast cancer: looking for the missing link between biology and treatments.
Giuseppe Palma, Giuseppe Frasci, +7 authors, Massimiliano D'Aiuto.
Oncotarget, 2015 Sep 21; 6(29). PMID: 26387133    Free PMC article.
Highly Cited. Review.
miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity.
Keith O'Brien, Michelle C Lowry, +7 authors, Lorraine O'Driscoll.
Oncotarget, 2015 Sep 30; 6(32). PMID: 26416415    Free PMC article.
A common promoter hypomethylation signature in invasive breast, liver and prostate cancer cell lines reveals novel targets involved in cancer invasiveness.
David Cheishvili, Barbara Stefanska, +7 authors, Moshe Szyf.
Oncotarget, 2015 Oct 03; 6(32). PMID: 26427334    Free PMC article.
Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer.
Teresa Di Desidero, Ping Xu, +2 authors, Robert S Kerbel.
Oncotarget, 2015 Dec 02; 6(40). PMID: 26623560    Free PMC article.
The fate of chemoresistance in triple negative breast cancer (TNBC).
Elma A O'Reilly, Luke Gubbins, +8 authors, Amanda McCann.
BBA Clin, 2015 Dec 18; 3. PMID: 26676166    Free PMC article.
Highly Cited. Review.
Tumor neovasculature-targeted cationic PEGylated liposomes of gambogic acid for the treatment of triple-negative breast cancer.
Ravi Doddapaneni, Ketan Patel, Ibtisam Hasan Owaid, Mandip Singh.
Drug Deliv, 2015 Dec 25; 23(4). PMID: 26701717    Free PMC article.
A Report of the Women's Health Congress Workshop on The Health of Women of Color: A Critical Intersection at the Corner of Sex/Gender and Race/Ethnicity.
Jennifer L Plank-Bazinet, Susan G Kornstein, +12 authors, Terri L Cornelison.
J Womens Health (Larchmt), 2016 Jan 16; 25(1). PMID: 26771559    Free PMC article.
Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu- positive advanced breast cancer: results of the CECOG LaVie trial.
Christiane Thallinger, Istvan Lang, +7 authors, Christoph Zielinski.
BMC Cancer, 2016 Feb 19; 16. PMID: 26887956    Free PMC article.
Substance P Receptor Signaling Mediates Doxorubicin-Induced Cardiomyocyte Apoptosis and Triple-Negative Breast Cancer Chemoresistance.
Prema Robinson, Moses Kasembeli, +3 authors, David J Tweardy.
Biomed Res Int, 2016 Mar 17; 2016. PMID: 26981525    Free PMC article.
G Protein Coupled Receptor Kinase 3 Regulates Breast Cancer Migration, Invasion, and Metastasis.
Matthew J Billard, David J Fitzhugh, +11 authors, Teresa K Tarrant.
PLoS One, 2016 Apr 07; 11(4). PMID: 27049755    Free PMC article.
Tamoxifen synergizes with 4-(E)-{(4-hydroxyphenylimino)-methylbenzene, 1,2-diol} and 4-(E)-{(p-tolylimino)-methylbenzene-1,2-diol}, novel azaresveratrol analogs, in inhibiting the proliferation of breast cancer cells.
Amruta Ronghe, Anwesha Chatterjee, +2 authors, Hari K Bhat.
Oncotarget, 2016 Jun 29; 7(32). PMID: 27351134    Free PMC article.
Anti-cancer efficacy of nonthermal plasma dissolved in a liquid, liquid plasma in heterogeneous cancer cells.
Ngoc Hoan Nguyen, Hyung Jun Park, +2 authors, Jong-Soo Lee.
Sci Rep, 2016 Jul 02; 6. PMID: 27364630    Free PMC article.
Metastatic breast cancer: The Odyssey of personalization.
A Sonnenblick, N Pondé, M Piccart.
Mol Oncol, 2016 Jul 20; 10(8). PMID: 27430154    Free PMC article.
Induction of apoptosis and G2/M arrest by ampelopsin E from Dryobalanops towards triple negative breast cancer cells, MDA-MB-231.
Napsiah Abd Rahman, Latifah Saiful Yazan, +7 authors, Sharida Fakurazi.
BMC Complement Altern Med, 2016 Sep 10; 16. PMID: 27609190    Free PMC article.
The DNA Damage Transducer RNF8 Facilitates Cancer Chemoresistance and Progression through Twist Activation.
Hong-Jen Lee, Chien-Feng Li, +4 authors, Chia-Hsin Chan.
Mol Cell, 2016 Sep 13; 63(6). PMID: 27618486    Free PMC article.
Local microRNA delivery targets Palladin and prevents metastatic breast cancer.
Avital Gilam, João Conde, +4 authors, Noam Shomron.
Nat Commun, 2016 Sep 20; 7. PMID: 27641360    Free PMC article.
Versatile Nanodelivery Platform to Maximize siRNA Combination Therapy.
Seung Koo Lee, Benedict Law, Ching-Hsuan Tung.
Macromol Biosci, 2016 Sep 23; 17(2). PMID: 27654639    Free PMC article.
Gold Nanoantenna-Mediated Photothermal Drug Delivery from Thermosensitive Liposomes in Breast Cancer.
Yu-Chuan Ou, Joseph A Webb, +7 authors, Rizia Bardhan.
ACS Omega, 2016 Sep 23; 1(2). PMID: 27656689    Free PMC article.
Optimized Method for Untargeted Metabolomics Analysis of MDA-MB-231 Breast Cancer Cells.
Amanda L Peterson, Adam K Walker, Erica K Sloan, Darren J Creek.
Metabolites, 2016 Sep 27; 6(4). PMID: 27669323    Free PMC article.
Current advances in biomarkers for targeted therapy in triple-negative breast cancer.
Brett Fleisher, Charlotte Clarke, Sihem Ait-Oudhia.
Breast Cancer (Dove Med Press), 2016 Oct 28; 8. PMID: 27785100    Free PMC article.
A network-based phenotype mapping approach to identify genes that modulate drug response phenotypes.
Junmei Cairns, Choong Yong Ung, +5 authors, Hu Li.
Sci Rep, 2016 Nov 15; 6. PMID: 27841317    Free PMC article.
Tryptophan hydroxylase 1 and 5-HT7 receptor preferentially expressed in triple-negative breast cancer promote cancer progression through autocrine serotonin signaling.
Jaya Gautam, Suhrid Banskota, +7 authors, Jung-Ae Kim.
Mol Cancer, 2016 Nov 23; 15(1). PMID: 27871326    Free PMC article.
Cyclooxygenase-2 regulates TGFβ-induced cancer stemness in triple-negative breast cancer.
Jun Tian, Mahmood Y Hachim, +5 authors, Jean Jacques Lebrun.
Sci Rep, 2017 Jan 06; 7. PMID: 28054666    Free PMC article.
Toxicity evaluation of magnetic hyperthermia induced by remote actuation of magnetic nanoparticles in 3D micrometastasic tumor tissue analogs for triple negative breast cancer.
Nathanael A Stocke, Pallavi Sethi, +4 authors, Meenakshi Upreti.
Biomaterials, 2017 Jan 06; 120. PMID: 28056401    Free PMC article.
STAT3/NF-κB-Regulated Lentiviral TK/GCV Suicide Gene Therapy for Cisplatin-Resistant Triple-Negative Breast Cancer.
Wei-Ying Kuo, Luen Hwu, +3 authors, Ren-Shyan Liu.
Theranostics, 2017 Mar 04; 7(3). PMID: 28255357    Free PMC article.
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
Aditya Bardia, Ingrid A Mayer, +19 authors, Linda T Vahdat.
J Clin Oncol, 2017 Mar 16; 35(19). PMID: 28291390    Free PMC article.
Highly Cited.
G protein-coupled KISS1 receptor is overexpressed in triple negative breast cancer and promotes drug resistance.
Alexandra Blake, Magdalena Dragan, +5 authors, Moshmi Bhattacharya.
Sci Rep, 2017 Apr 20; 7. PMID: 28422142    Free PMC article.
Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population.
Jorge Gómez-Miragaya, Marta Palafox, +19 authors, Eva González-Suárez.
Stem Cell Reports, 2017 May 02; 8(5). PMID: 28457887    Free PMC article.
Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer.
Anastasia A Ionkina, John J Tentler, +9 authors, Jennifer R Diamond.
Front Oncol, 2017 May 31; 7. PMID: 28555173    Free PMC article.
GROα overexpression drives cell migration and invasion in triple negative breast cancer cells.
Kruttika Bhat, Marianna Sarkissyan, Yanyuan Wu, Jaydutt V Vadgama.
Oncol Rep, 2017 Jun 01; 38(1). PMID: 28560447    Free PMC article.
Prediction of adjuvant chemotherapy response in triple negative breast cancer with discovery and targeted proteomics.
Angelo Gámez-Pozo, Lucía Trilla-Fuertes, +10 authors, Juan Ángel Fresno Vara.
PLoS One, 2017 Jun 09; 12(6). PMID: 28594844    Free PMC article.
C-reactive protein binds to integrin α2 and Fcγ receptor I, leading to breast cell adhesion and breast cancer progression.
E-S Kim, S Y Kim, +7 authors, A Moon.
Oncogene, 2017 Aug 29; 37(1). PMID: 28846105
Tumor-initiating CD49f cells are a hallmark of chemoresistant triple negative breast cancer.
Jorge Gomez-Miragaya, Eva González-Suárez.
Mol Cell Oncol, 2017 Sep 05; 4(4). PMID: 28868349    Free PMC article.
Kaiso is highly expressed in TNBC tissues of women of African ancestry compared to Caucasian women.
Blessing I Bassey-Archibong, Shawn M Hercules, +9 authors, Juliet M Daniel.
Cancer Causes Control, 2017 Sep 10; 28(11). PMID: 28887687    Free PMC article.
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.
Luc Y Dirix, Istvan Takacs, +15 authors, Erika P Hamilton.
Breast Cancer Res Treat, 2017 Oct 25; 167(3). PMID: 29063313    Free PMC article.
Highly Cited.
EZH2 and histone deacetylase inhibitors induce apoptosis in triple negative breast cancer cells by differentially increasing H3 Lys27 acetylation in the BIM gene promoter and enhancers.
Julia P Huang, Kun Ling.
Oncol Lett, 2017 Nov 09; 14(5). PMID: 29113202    Free PMC article.
Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?
M E Cazzaniga, L Cortesi, +14 authors, E Rulli.
Int J Breast Cancer, 2018 Jan 16; 2017. PMID: 29333297    Free PMC article.
Prediction of novel target genes and pathways involved in bevacizumab-resistant colorectal cancer.
Precious Takondwa Makondi, Chia-Hwa Lee, +3 authors, Po-Li Wei.
PLoS One, 2018 Jan 18; 13(1). PMID: 29342159    Free PMC article.
Three-dimensional tumor model mimics stromal - breast cancer cells signaling.
Stephanie Lemmo Ham, Pradip Shahi Thakuri, +4 authors, Hossein Tavana.
Oncotarget, 2018 Feb 09; 9(1). PMID: 29416611    Free PMC article.
Knockdown of microRNA-29a regulates the expression of apoptosis-related genes in MCF-7 breast carcinoma cells.
Gholamreza Khamisipour, Elham Mansourabadi, +6 authors, Shakib Shamsian.
Mol Clin Oncol, 2018 Feb 13; 8(2). PMID: 29435304    Free PMC article.
Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.
Kendra L Schwartz, Michael S Simon, +7 authors, Ruben G W Quek.
Cancer, 2018 Mar 06; 124(10). PMID: 29505670    Free PMC article.
Jana S Miles, Samantha J Sojourner, +3 authors, Hernan Flores-Rozas.
Int J Adv Res (Indore), 2018 Apr 17; 6(3). PMID: 29657945    Free PMC article.
Five-Part Pentameric Nanocomplex Shows Improved Efficacy of Doxorubicin in CD44+ Cancer Cells.
Nathan Beals, Praveena S Thiagarajan, +4 authors, Soumitra Basu.
ACS Omega, 2018 Jul 20; 2(11). PMID: 30023561    Free PMC article.
Modeling of mesenchymal hybrid epithelial state and phenotypic transitions in EMT and MET processes of cancer cells.
Peng He, Kang Qiu, Ya Jia.
Sci Rep, 2018 Sep 27; 8(1). PMID: 30254295    Free PMC article.
Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells.
Estefanía Paula Juliá, Analía Amante, +2 authors, Estrella Mariel Levy.
Front Immunol, 2018 Oct 09; 9. PMID: 30294328    Free PMC article.
Dynamin impacts homology-directed repair and breast cancer response to chemotherapy.
Sophia B Chernikova, Rochelle B Nguyen, +15 authors, J Martin Brown.
J Clin Invest, 2018 Oct 30; 128(12). PMID: 30371505    Free PMC article.
Nanoparticle Encapsulation of Synergistic Immune Agonists Enables Systemic Codelivery to Tumor Sites and IFNβ-Driven Antitumor Immunity.
Prabhani U Atukorale, Shruti P Raghunathan, +8 authors, Efstathios Karathanasis.
Cancer Res, 2019 Aug 23; 79(20). PMID: 31431457    Free PMC article.
Differentially expressed microRNAs in exosomes of patients with breast cancer revealed by next‑generation sequencing.
Heming Wu, Qiuming Wang, +4 authors, Zhikang Yu.
Oncol Rep, 2019 Nov 21; 43(1). PMID: 31746410    Free PMC article.
Prognostic factors and survival outcomes according to tumor subtype in patients with breast cancer lung metastases.
Siying Chen, Jin Yang, +3 authors, Jun Lyu.
PeerJ, 2019 Dec 25; 7. PMID: 31871847    Free PMC article.
Effective treatment of cancer metastasis using a dual-ligand nanoparticle.
Gil Covarrubias, Felicia He, +4 authors, Efstathios Karathanasis.
PLoS One, 2019 Jul 30; 14(7). PMID: 31356633    Free PMC article.
The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors.
Eduardo Tormo, Sandra Ballester, +11 authors, Pilar Eroles.
Sci Rep, 2019 Mar 31; 9(1). PMID: 30926829    Free PMC article.
Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells.
Jun Tian, Fatmah Al Raffa, +7 authors, Jean-Jacques Lebrun.
Br J Cancer, 2018 Nov 30; 119(12). PMID: 30482914    Free PMC article.
Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment.
Ana C Garrido-Castro, Nancy U Lin, Kornelia Polyak.
Cancer Discov, 2019 Jan 27; 9(2). PMID: 30679171    Free PMC article.
Highly Cited. Review.
Tofacitinib enhances delivery of antibody-based therapeutics to tumor cells through modulation of inflammatory cells.
Nathan Simon, Antonella Antignani, +3 authors, David FitzGerald.
JCI Insight, 2019 Feb 06; 4(5). PMID: 30720466    Free PMC article.
Anti-cancer Activity of Centipeda minima Extract in Triple Negative Breast Cancer via Inhibition of AKT, NF-κB, and STAT3 Signaling Pathways.
Magnolia Muk-Lan Lee, Brandon Dow Chan, +7 authors, William Chi-Shing Tai.
Front Oncol, 2020 Apr 25; 10. PMID: 32328465    Free PMC article.
Polymorphisms in PARP1 predict disease-free survival of triple-negative breast cancer patients treated with anthracycline/taxane based adjuvant chemotherapy.
Yuqian Liao, Yulu Liao, +2 authors, Ying Fan.
Sci Rep, 2020 May 02; 10(1). PMID: 32355298    Free PMC article.
Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs.
Tejaswini P Reddy, Dong S Choi, +7 authors, Roberto R Rosato.
Breast Cancer Res, 2020 May 18; 22(1). PMID: 32414394    Free PMC article.
Tumor cell lysate-loaded immunostimulatory spherical nucleic acids as therapeutics for triple-negative breast cancer.
Cassandra E Callmann, Lisa E Cole, +3 authors, Chad A Mirkin.
Proc Natl Acad Sci U S A, 2020 Jul 17; 117(30). PMID: 32669433    Free PMC article.
Nucleus-enriched Ruthenium Polypyridine Complex Acts as a Potent Inhibitor to Suppress Triple-negative Breast Cancer Metastasis In vivo.
Xuanhao Zhao, Li Li, +5 authors, Wenjie Mei.
Comput Struct Biotechnol J, 2018 Dec 26; 17. PMID: 30581541    Free PMC article.
Cytotoxicity of the Urokinase-Plasminogen Activator Inhibitor Carbamimidothioic Acid (4-Boronophenyl) Methyl Ester Hydrobromide (BC-11) on Triple-Negative MDA-MB231 Breast Cancer Cells.
Alessandra Longo, Mariangela Librizzi, +3 authors, Claudio Luparello.
Molecules, 2015 Jun 02; 20(6). PMID: 26029857    Free PMC article.
Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors.
Yanrong Su, Nathan R Hopfinger, +3 authors, Jose Russo.
J Exp Clin Cancer Res, 2018 Dec 15; 37(1). PMID: 30547810    Free PMC article.
Intermediate cell states in epithelial-to-mesenchymal transition.
Yutong Sha, Daniel Haensel, +3 authors, Qing Nie.
Phys Biol, 2018 Dec 19; 16(2). PMID: 30560804    Free PMC article.
Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer.
Daphne Brisard, Frank Eckerdt, +5 authors, Leonidas C Platanias.
Oncotarget, 2019 Jan 17; 9(99). PMID: 30647871    Free PMC article.
In Vitro Bioassay-Guided Identification of Anticancer Properties from Moringa oleifera Lam. Leaf against the MDA-MB-231 Cell Line.
Prapakorn Wisitpongpun, Nungruthai Suphrom, +3 authors, Kanchana Usuwanthim.
Pharmaceuticals (Basel), 2020 Dec 19; 13(12). PMID: 33333817    Free PMC article.
Long Non-Coding RNA PVT1 Regulates the Resistance of the Breast Cancer Cell Line MDA-MB-231 to Doxorubicin via Nrf2.
Ying Luo, Wei Zhang, +3 authors, Lin Yuan.
Technol Cancer Res Treat, 2020 Dec 18; 19. PMID: 33327894    Free PMC article.
Dormant Tumor Cell Vaccination: A Mathematical Model of Immunological Dormancy in Triple-Negative Breast Cancer.
Reza Mehdizadeh, Seyed Peyman Shariatpanahi, +2 authors, Curzio Rüegg.
Cancers (Basel), 2021 Jan 15; 13(2). PMID: 33440806    Free PMC article.
Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma.
Raza Syed Hoda, Edi Brogi, +10 authors, Hannah Yong Wen.
Mod Pathol, 2020 Jul 03; 33(11). PMID: 32612248    Free PMC article.
Progress in systemic therapy for triple-negative breast cancer.
Hongnan Mo, Binghe Xu.
Front Med, 2020 Aug 14; 15(1). PMID: 32789731
Identification of MFGE8 and KLK5/7 as mediators of breast tumorigenesis and resistance to COX-2 inhibition.
Jun Tian, Vivian Wang, +5 authors, Jean-Jacques Lebrun.
Breast Cancer Res, 2021 Feb 17; 23(1). PMID: 33588911    Free PMC article.
Altered gene expression in glycolysis-cholesterol synthesis axis correlates with outcome of triple-negative breast cancer.
Peng-Cheng Zhong, Rong Shu, +3 authors, Ying-Jie Hu.
Exp Biol Med (Maywood), 2020 Nov 28; 246(5). PMID: 33243007    Free PMC article.
Selection of aptamers against triple negative breast cancer cells using high throughput sequencing.
Débora Ferreira, Joaquim Barbosa, +5 authors, Ligia R Rodrigues.
Sci Rep, 2021 Apr 23; 11(1). PMID: 33883615    Free PMC article.
Prognostic Significance and Tumor Immune Microenvironment Heterogenicity of m5C RNA Methylation Regulators in Triple-Negative Breast Cancer.
Zhidong Huang, Junfan Pan, +4 authors, Debo Chen.
Front Cell Dev Biol, 2021 May 01; 9. PMID: 33928086    Free PMC article.
Regulation of Cellular and Cancer Stem Cell-Related Putative Gene Expression of Parental and CD44+CD24- Sorted MDA-MB-231 Cells by Cisplatin.
May Zie Koh, Wan Yong Ho, +3 authors, Noorjahan Banu Alitheen.
Pharmaceuticals (Basel), 2021 May 01; 14(5). PMID: 33919109    Free PMC article.
Combination Therapy, a Promising Approach to Enhance the Efficacy of Radionuclide and Targeted Radionuclide Therapy of Prostate and Breast Cancer.
Tyrillshall S T Damiana, Simone U Dalm.
Pharmaceutics, 2021 Jun 03; 13(5). PMID: 34067215    Free PMC article.
Chemotherapy Shifts the Balance in Favor of CD8+ TNFR2+ TILs in Triple-Negative Breast Tumors.
Tamir Baram, Nofar Erlichman, +7 authors, Adit Ben-Baruch.
Cells, 2021 Jul 03; 10(6). PMID: 34201054    Free PMC article.
CBP/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers.
Aaron R Waddell, Haojie Huang, Daiqing Liao.
Cancers (Basel), 2021 Jul 03; 13(12). PMID: 34201346    Free PMC article.
Screening of DNA Damage Repair Genes Involved in the Prognosis of Triple-Negative Breast Cancer Patients Based on Bioinformatics.
Nan Wang, Yuanting Gu, +6 authors, Lin Li.
Front Genet, 2021 Aug 20; 12. PMID: 34408776    Free PMC article.
LightSpot®-FL-1 Fluorescent Probe: An Innovative Tool for Cancer Drug Resistance Analysis by Direct Detection and Quantification of the P-glycoprotein (P-gp) on Monolayer Culture and Spheroid Triple Negative Breast Cancer Models.
Antoine Goisnard, Pierre Daumar, +8 authors, Mahchid Bamdad.
Cancers (Basel), 2021 Aug 28; 13(16). PMID: 34439204    Free PMC article.
Immunotherapy Treatment for Triple Negative Breast Cancer.
Elizabeth R Berger, Tristen Park, +3 authors, Nita Ahuja.
Pharmaceuticals (Basel), 2021 Aug 29; 14(8). PMID: 34451860    Free PMC article.
Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities.
Laura M Spring, Erika Nakajima, +6 authors, Aditya Bardia.
Oncologist, 2021 Jun 28; 26(10). PMID: 34176192    Free PMC article.
Sacituzumab govitecan in metastatic triple negative breast cancer (TNBC): Four design features in the ASCENT trial potentially favored the experimental arm.
Timothee Olivier, Vinay Prasad.
Transl Oncol, 2021 Oct 24; 15(1). PMID: 34688044    Free PMC article.